Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

Insider Buying and Selling In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...